245 related articles for article (PubMed ID: 20078617)
1. The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men.
Kohlrausch FB; de Cássia Estrela R; Barroso PF; Suarez-Kurtz G
Br J Clin Pharmacol; 2010 Jan; 69(1):95-8. PubMed ID: 20078617
[TBL] [Abstract][Full Text] [Related]
2. CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children.
Rakhmanina NY; Neely MN; Van Schaik RH; Gordish-Dressman HA; Williams KD; Soldin SJ; van den Anker JN
Ther Drug Monit; 2011 Aug; 33(4):417-24. PubMed ID: 21743379
[TBL] [Abstract][Full Text] [Related]
3. ABCB1 polymorphisms and the concentrations of lopinavir and ritonavir in blood, semen and saliva of HIV-infected men under antiretroviral therapy.
Estrela Rde C; Ribeiro FS; Barroso PF; Tuyama M; Gregório SP; Dias-Neto E; Struchiner CJ; Suarez-Kurtz G
Pharmacogenomics; 2009 Feb; 10(2):311-8. PubMed ID: 19207033
[TBL] [Abstract][Full Text] [Related]
4. Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults.
Schipani A; Egan D; Dickinson L; Davies G; Boffito M; Youle M; Khoo SH; Back DJ; Owen A
Antivir Ther; 2012; 17(5):861-8. PubMed ID: 22477766
[TBL] [Abstract][Full Text] [Related]
5. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms.
Hartkoorn RC; Kwan WS; Shallcross V; Chaikan A; Liptrott N; Egan D; Sora ES; James CE; Gibbons S; Bray PG; Back DJ; Khoo SH; Owen A
Pharmacogenet Genomics; 2010 Feb; 20(2):112-20. PubMed ID: 20051929
[TBL] [Abstract][Full Text] [Related]
6. Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146.
Zhang X; Tierney C; Albrecht M; Demeter LM; Morse G; DiFrancesco R; Dykes C; Jiang H; Haas DW
Ther Drug Monit; 2013 Apr; 35(2):209-16. PubMed ID: 23503447
[TBL] [Abstract][Full Text] [Related]
7. Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus.
Liu X; Ma Q; Zhao Y; Mu W; Sun X; Cheng Y; Zhang H; Ma Y; Zhang F
Pharmacotherapy; 2017 Sep; 37(9):1073-1080. PubMed ID: 28718515
[TBL] [Abstract][Full Text] [Related]
8. CYP3A5 genotype has no impact on plasma trough concentrations of lopinavir and ritonavir in HIV-infected subjects.
Estrela RC; Santoro AB; Barroso PF; Tuyama M; Suarez-Kurtz G
Clin Pharmacol Ther; 2008 Aug; 84(2):205-7. PubMed ID: 18288082
[TBL] [Abstract][Full Text] [Related]
9. Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers.
Daka A; Dimovski A; Kapedanovska A; Vavlukis M; Eftimov A; Labachevski N; Jakjovski K; Geshkovska MN; Nebija D; Mladenovska K
Pharmazie; 2015 Jul; 70(7):480-8. PubMed ID: 26373210
[TBL] [Abstract][Full Text] [Related]
10. Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir trough concentrations in HIV-infected patients.
Calza L; Mosca L; Pocaterra D; Piergentili B; Colangeli V; Manfredi R; Erario A; Grossi G; Verucchi G; Viale P
Eur J Clin Pharmacol; 2011 Feb; 67(2):143-9. PubMed ID: 20878151
[TBL] [Abstract][Full Text] [Related]
11. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population.
Pasanen MK; Backman JT; Neuvonen PJ; Niemi M
Eur J Clin Pharmacol; 2006 Jun; 62(6):409-15. PubMed ID: 16758257
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.
Yilmaz A; Ståhle L; Hagberg L; Svennerholm B; Fuchs D; Gisslén M
Scand J Infect Dis; 2004; 36(11-12):823-8. PubMed ID: 15764168
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients.
Moltó J; Xinarianos G; Miranda C; Pushpakom S; Cedeño S; Clotet B; Owen A; Valle M
Clin Pharmacokinet; 2013 Jul; 52(7):543-53. PubMed ID: 23494984
[TBL] [Abstract][Full Text] [Related]
14. Influence of SLCO1B1 polymorphisms on lopinavir C
Dragović G; Dimitrijević B; Kušić J; Soldatović I; Jevtović D; Olagunju A; Owen A
Br J Clin Pharmacol; 2020 Jul; 86(7):1289-1295. PubMed ID: 32022294
[TBL] [Abstract][Full Text] [Related]
15. CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults.
Olagunju A; Schipani A; Siccardi M; Egan D; Khoo S; Back D; Owen A
Pharmacogenet Genomics; 2014 Sep; 24(9):459-63. PubMed ID: 24950369
[TBL] [Abstract][Full Text] [Related]
16. Changes in body fat composition after 1 year of salvage therapy with lopinavir/ritonavir-containing regimens and its relationship with lopinavir plasma concentrations.
Gutiérrez F; Padilla S; Masiá M; Navarro A; Gallego J; Hernández I; Ramos JM; Martin-Hidalgo A
Antivir Ther; 2004 Feb; 9(1):105-13. PubMed ID: 15040542
[TBL] [Abstract][Full Text] [Related]
17. CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics.
Zhou Q; Chen QX; Ruan ZR; Yuan H; Xu HM; Zeng S
Pharmazie; 2013 Mar; 68(3):187-94. PubMed ID: 23556337
[TBL] [Abstract][Full Text] [Related]
18. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.
Lubomirov R; di Iulio J; Fayet A; Colombo S; Martinez R; Marzolini C; Furrer H; Vernazza P; Calmy A; Cavassini M; Ledergerber B; Rentsch K; Descombes P; Buclin T; Decosterd LA; Csajka C; Telenti A;
Pharmacogenet Genomics; 2010 Apr; 20(4):217-30. PubMed ID: 20139798
[TBL] [Abstract][Full Text] [Related]
19. SLCO1B1 gene variability influences lipid-lowering efficacy on simvastatin therapy in Southern Brazilians.
Sortica VA; Fiegenbaum M; Lima LO; Van der Sand CR; Van der Sand LC; Ferreira ME; Pires RC; Hutz MH
Clin Chem Lab Med; 2012 Mar; 50(3):441-8. PubMed ID: 22505549
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy.
Lambert JS; Else LJ; Jackson V; Breiden J; Gibbons S; Dickinson L; Back DJ; Brennan M; Connor EO; Boyle N; Fleming C; Coulter-Smith S; Khoo SH
HIV Med; 2011 Mar; 12(3):166-73. PubMed ID: 20726906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
